SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 7,393 Shares

Posted by on Jul 8th, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.16, for a total value of $38,147.88. Following the completion of the transaction, the insider directly owned 233,387 shares in the company, valued at $1,204,276.92. This represents a 3.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

  • On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total transaction of $27,500.00.
  • On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.95, for a total transaction of $24,750.00.
  • On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.82, for a total transaction of $24,100.00.
  • On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.20, for a total transaction of $3,161.60.
  • On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total transaction of $7,936.00.
  • On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total transaction of $20,944.00.
  • On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total transaction of $17,433.00.
  • On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,152.94.
  • On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.

SOPHiA GENETICS Trading Up 1.9%

NASDAQ SOPH opened at $5.44 on Wednesday. The firm’s 50 day moving average price is $5.13 and its two-hundred day moving average price is $4.97. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. SOPHiA GENETICS SA has a twelve month low of $2.92 and a twelve month high of $6.30. The stock has a market cap of $456.36 million, a price-to-earnings ratio of -10.46 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

  • Positive Sentiment: The insider sales were mostly routine, pre-planned transactions tied to equity-award vesting and tax withholding, which suggests they may not signal a fundamental change in the business or management’s outlook.
  • Neutral Sentiment: Multiple executives and directors, including Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, and others, reported sales in the same period, increasing investor focus on insider activity.
  • Negative Sentiment: Even if planned, the cluster of insider share sales can create pressure on sentiment because it may be interpreted as reduced confidence or excess supply in the stock near term.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SOPH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.50.

View Our Latest Analysis on SOPH

Institutional Investors Weigh In On SOPHiA GENETICS

Large investors have recently made changes to their positions in the company. 1492 Capital Management LLC acquired a new position in SOPHiA GENETICS in the fourth quarter worth approximately $973,000. Royce & Associates LP acquired a new position in shares of SOPHiA GENETICS during the 4th quarter worth $2,009,000. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the 1st quarter valued at $2,157,000. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS during the 3rd quarter valued at $49,000. Finally, Royal Bank of Canada lifted its stake in shares of SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the last quarter. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

Featured Articles

Insider Buying and Selling by Quarter for SOPHiA GENETICS (NASDAQ:SOPH)

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.